Whey Protein Micelles and Thermogenesis in Overweight Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-11-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of the trial is to measure the thermogenic effect of two different doses of whey protein microgels.

It will be a randomized crossover double-blind design conducted in 20 subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Whey Protein Pre-meals on Post-prandial Glucose

NCT05112146

Prediabetic State

COMPLETED NA

Effect of Acute Intake of Meals Containing Higher vs. Lower Energy From Protein on DIT

NCT06494449

Healthy Overweight and Obesity

COMPLETED NA

Whey Protein, Resistance Training, and Changes in Body Composition

NCT01186536

Obesity

COMPLETED NA

Effects of Milk Protein Concentrate on Overall Health During Weight Loss in Overweight/Obese Adults

NCT01692860

Sarcopenia Metabolic Disease High Blood Pressure

COMPLETED NA

The Effect of Nutritional Interventions on Exercise-induced Muscle Damage

NCT02839525

Muscle Damage

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary objective and outcome:

The primary objective of the trial is to measure the thermogenic effect of two different doses of whey protein microgels (WPM).

Secondary objectives and outcomes:

Explore the mechanism of action of WPM on thermogenesis including:

Protein turnover in response to the dose and the source of protein (WPM versus casein) Insulinemic and glycemic response to the dose and source of protein (WPM versus casein)

Design: The proposed study is a randomized double-blind, placebo-controlled, single center, crossover design.

At the start of the study, subjects will be randomly assigned to 4 different groups in a crossover design, where they will be asked to consume a beverage containing Product 1: 0g of protein (maltodextrin control) Product 2: 30g of WPM Product 3: 50g of WPM Product 4: 50g of micellar casein (MC) Number of subjects: The number of subjects will be 15. Sufficient subjects should be recruited to provide a 30% drop-out rate. Therefore 20 subjects will be needed including drop-outs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control (WPM 0)

400 mL beverage with 85.0% maltodextrine, 15.0% fat and 0% of whey protein micelles Product given once after 1 hour of monitoring for baseline

Group Type PLACEBO_COMPARATOR

WPM 30

Intervention Type OTHER

43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM

WPM 50

Intervention Type OTHER

16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM

MC 50

Intervention Type OTHER

16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC

WPM 30

400 mL beverage with 43.7% of maltodextrine, 15.2 % fat and 41.1% (30 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline

Group Type ACTIVE_COMPARATOR

Control (WPM 0)

Intervention Type OTHER

85.0 % maltodextrin,15.0% fat, 0% WPM

WPM 50

Intervention Type OTHER

16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM

MC 50

Intervention Type OTHER

16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC

WPM 50

400 mL beverage with 16.3% of maltodextrine, 15.2 % fat and 68.5% (50 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline

Group Type ACTIVE_COMPARATOR

Control (WPM 0)

Intervention Type OTHER

85.0 % maltodextrin,15.0% fat, 0% WPM

WPM 30

Intervention Type OTHER

43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM

MC 50

Intervention Type OTHER

16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC

MC 50

400 mL beverage with 16.7% of maltodextrine, 15.0 % fat and 68.2% (50 g) of whey protein micelles 50 g of micellar casein Product given once after 1 hour of monitoring for baseline

Group Type ACTIVE_COMPARATOR

Control (WPM 0)

Intervention Type OTHER

85.0 % maltodextrin,15.0% fat, 0% WPM

WPM 30

Intervention Type OTHER

43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM

WPM 50

Intervention Type OTHER

16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Control (WPM 0)

85.0 % maltodextrin,15.0% fat, 0% WPM

Intervention Type OTHER

WPM 30

43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM

Intervention Type OTHER

WPM 50

16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM

Intervention Type OTHER

MC 50

16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Overweight (BMI range between 25.0 and 29.9 kg per m2 Healthy Having obtained his/her subjects over 20 year informed consent.

Exclusion Criteria

Chronic or acute diseases affecting protein metabolism (diabetes, renal insufficiency, CVD, liver disease), dyslipidemia History of varicose or venous stases Recent major surgery (3 months) History of major gastro-intestinal surgery (gastric bypass, intestinal resection etc…) Malabsorption disorders History of cancer within the past year Significant weight loss during the last 3 months Food allergies, especially cow milk protein. Pregnancy or lactation Special diets especially vegetarian, high protein (≥ 1.6 g/kg) or weight loss program Abnormal Food Frequency Questionnaire Aversion to vanilla or chocolate aromas Smoking Moderate to intense physical activity \> 2 hours/week Hematocrit \<40 for males and \< 36 for females Blood donation within 3 months of study start and 3 months after study end Regular consumption of medication and supplements i.e. any treatment affecting thermogenesis or nutrient metabolism in general such as corticosteroids, insulin, androgens, antibiotics and nutritional supplements (multivitamins, protein shakes).

Have a high alcohol consumption (more than 1 drink/day) Consumption of illicit drugs Subject who cannot be expected to comply with the study procedures, including consuming the test products.

Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study.

Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes